Therapeutic plasma exchange (TPE) is a medical procedure in which blood is drawn from a patient, the plasma component is separated and removed, and the blood cells are returned combined with a replacement fluid — typically a 5% albumin solution or fresh frozen plasma.
Plasma is the liquid portion of blood — roughly 55% of total blood volume — and it is where much of the biochemical activity of the circulatory system occurs. Plasma carries proteins, antibodies, clotting factors, hormones, inflammatory signaling molecules, lipoproteins, and, as research increasingly documents, accumulated factors that rise with age and contribute to chronic disease processes.
TPE has been used in clinical medicine for decades, originally for autoimmune and neurological conditions where circulating antibodies or pathologic proteins drive disease. The American Society for Apheresis (ASFA) has classified evidence-based indications across more than 80 clinical conditions, ranging from first-line applications in acute neurological crises to investigational applications in longevity and inflammatory disease.
More recently, a growing body of research — beginning with parabiosis experiments in 2005 and extending through randomized clinical trials published in 2025 — has explored how modifying plasma composition may influence aging-related biological markers and inflammatory signaling. This research has moved from animal models to early human trials over two decades. For a practical clinical overview of how these principles are applied in an outpatient setting, a detailed clinical overview is available in Avinity’s PlasmaRestore™ therapeutic plasma exchange protocol.
80+
Clinical conditions for which the ASFA has published tiered evidence-based recommendations for therapeutic apheresis
ASFA Guidelines — Journal of Clinical Apheresis (periodically updated)~63%
Of circulating plasma substances removed in a single-volume exchange — approximately 75–80% removed at 1.5 plasma volumes
Apheresis practice literature; Morse, 20262005
Year the parabiosis research began supporting the broader hypothesis that circulating plasma factors influence aging biology — research later translated toward plasma exchange applications
Conboy et al., Nature, 2005 · PMID 15716955TPE does not act on a single biological pathway. It works by changing the composition of circulating plasma — reducing accumulated substances that influence how cells communicate, how the immune system behaves, and how tissues respond to chronic inflammatory burden.
A growing body of research suggests that circulating plasma factors may play a larger role in age-related decline than previously understood — and that these factors accumulate over time rather than simply declining. The key implication: diluting or removing those accumulated factors, rather than adding "young" factors, appears to drive the biological effects observed in animal and early human studies.
During a TPE session, blood is continuously processed through an apheresis machine that separates plasma from blood cells using centrifugation or filtration. The plasma — carrying whatever circulating substances are being targeted — is discarded. Blood cells are returned to the patient with replacement fluid, typically 5% albumin.
The distinction from drug therapy matters. Medications work by blocking pathways or slowing the production of harmful substances. TPE physically removes what's already circulating — rather than modulating a single signaling pathway. For protein-bound substances, large-molecular-weight compounds, and factors the kidneys and liver can't easily filter, this can produce a more direct and immediate reduction in circulating burden.ASFA guidelines
What TPE Removes From Circulation
- Pro-inflammatory cytokines and inflammatory signaling proteins (established in clinical literature)
- Pathogenic autoantibodies and immune complexes driving autoimmune-mediated tissue damage (ASFA Category I–II)
- Misfolded or aggregated proteins associated with neurodegenerative conditions (investigational)
- Lipoproteins — including LDL and lipoprotein(a) — in specific cardiovascular applications (Waldmann & Parhofer, 2016)
- Protein-bound heavy metals including mercury, in specialized apheresis protocols (clinical case literature)
- Senescence-associated secretory proteins that accumulate with biological aging (Kim et al., 2022; Fuentealba et al., 2025)
Investigational research is also exploring whether plasma exchange may influence the circulation of certain environmental contaminants and protein-bound compounds not easily cleared through other means. Research in this area remains preliminary and unpublished for most applications.
On Environmental Contaminant ResearchThe documented clinical application of TPE for heavy metal reduction (including mercury) is supported by case literature. Research exploring whether plasma exchange may influence circulating environmental contaminants more broadly is early-stage, investigational, and not yet peer-reviewed. These applications should not be interpreted as established indications. Physician evaluation is required before any application of TPE.
The Replacement Fluid: Why It Matters — and What the Options Are
When plasma is removed, it must be replaced with a fluid that restores volume and maintains physiologic pressure — otherwise the patient cannot tolerate the procedure. The choice of replacement fluid is not cosmetic. It determines what is reintroduced alongside the volume, what risks accompany the exchange, and in some contexts, whether the procedure produces additional biological effects beyond simple removal.ASFA 2023
| Replacement Fluid | 5% Albumin | Fresh Frozen Plasma (FFP) | IVIG + Albumin |
|---|
| Primary Use | Elective, outpatient, and longevity-focused TPE protocols | Acute hospital settings; conditions requiring clotting factor replacement | Investigational longevity protocols; autoimmune TPE requiring immunoglobulin replenishment |
| What It Provides | Restores plasma volume and oncotic pressure without introducing donor antibodies | Full plasma protein replacement including clotting factors and donor immunoglobulins | Albumin volume replacement plus concentrated immunoglobulin support |
| Donor Antibody Risk | None — processed to remove immunoglobulins | Present — introduces all donor antibodies; increases TRALI risk | Present — IVIG contains concentrated donor immunoglobulins |
| Requires Blood Typing | No | Yes — ABO-compatible FFP required | No (albumin component); IVIG does not require typing |
| Research Evidence | Most-studied in longevity context; Mehdipour 2020 proteomic findings, Kim 2022, Fuentealba 2025 | ASFA Category I–II for specific indications (TTP, liver failure, HUS) | Fuentealba 2025 Circulate Trial — TPE + IVIG arm produced strongest biological age reduction (~2.61 years epigenetic change) |
| Relative Cost | Moderate — most cost-effective for elective protocols | Moderate — but requires additional blood bank processing | Significantly higher — IVIG adds substantial per-session cost |
5% albumin is the standard replacement fluid for elective outpatient and longevity-focused TPE. It restores plasma oncotic pressure and volume while avoiding the introduction of donor antibodies that accompany fresh frozen plasma — reducing the risk of transfusion-related acute lung injury (TRALI) and allergic reactions.Kaplan 2014 In the research context, proteomic analysis of plasma samples following albumin-based TPE showed a reduction in age-associated inflammatory proteins alongside an increase in certain proteins linked to cellular repair — a pattern consistent with the hypothesis that accumulated circulating factors may have been suppressing the body's own regulatory mechanisms.Mehdipour 2020
Fresh frozen plasma (FFP) is the preferred replacement fluid when clotting factor replenishment is clinically necessary — for example, in thrombotic thrombocytopenic purpura (TTP), where plasma also provides a missing enzyme (ADAMTS13) that albumin cannot. ASFA guidelines specify indications where FFP is required over albumin.ASFA 2023 For elective and investigational outpatient TPE, FFP is generally not the preferred choice due to its immunologic complexity and logistical requirements.
IVIG (intravenous immunoglobulin) is not a replacement fluid in the traditional sense — it is a concentrated immunoglobulin preparation administered alongside albumin replacement. In the 2025 Circulate Trial (Fuentealba, Kiprov et al.), the arm combining biweekly TPE with IVIG produced the strongest measurable reduction in epigenetic aging markers (~2.61 years after three sessions) compared to TPE-only arms.Fuentealba 2025 The mechanism is not fully established — IVIG may replenish beneficial immunoglobulins removed during exchange, provide immunomodulatory effects, or both. IVIG adds significant cost and is not standard in current elective longevity protocols, but it represents an area of active investigation.
Replacement Fluid Selection Requires Physician JudgmentThe appropriate replacement fluid depends on the clinical indication, the patient's coagulation status, and the goals of treatment. There is no universal protocol. ASFA guidelines provide evidence-based recommendations by indication, but their application to elective and investigational longevity contexts requires individualized physician evaluation. Patients should ask specifically which replacement fluid will be used and why.
Search engines and popular health content frequently conflate these three terms. They refer to distinct processes with different purposes, settings, and clinical implications.
| Factor | Plasma Donation | Plasmapheresis (General) | Therapeutic Plasma Exchange (TPE) |
|---|
| Primary Purpose | Donor contributes plasma for pharmaceutical manufacturing or transfusions | Broad term for any process separating plasma from blood | Physician-prescribed procedure to remove circulating substances from the patient's blood |
| Who It Serves | Plasma banks and pharmaceutical manufacturers | Varies — encompasses donation and treatment contexts | The patient receiving the procedure |
| Replacement Fluid | None — donor plasma is kept, blood cells returned | Depends on application | 5% albumin or fresh frozen plasma returned to patient |
| Clinical Setting | Plasma donation center | Medical or donation setting depending on type | Physician-supervised clinical or outpatient apheresis facility |
| Medical Oversight | Minimal — standardized screening process | Varies widely | Required — physician evaluation, monitoring, and follow-up |
| Exchange Volume | Fixed per donation center protocol | Varies | Individualized to patient total plasma volume (calculated from body weight and hematocrit) |
| Compensation / Cost | Donor is compensated ($50–$150 per session) | — | Patient pays; insurance coverage is indication-dependent |
Search Intent NoteQueries like "plasma exchange near me" frequently return plasma donation centers alongside TPE clinics. Patients researching therapeutic plasma exchange should confirm they are reviewing a physician-prescribed clinical procedure — not a plasma collection facility. The presence of compensation, fixed session protocols, and the absence of physician evaluation are indicators of a donation context, not a therapeutic one.
The scientific basis for TPE as a longevity and investigational health intervention developed over two decades, progressing from foundational animal studies to randomized clinical trials in humans. The following summarizes the key studies in chronological sequence.
Research ContextThe studies below span a range of contexts — preclinical animal research, observational clinical studies, and randomized controlled trials. Findings from animal models do not necessarily translate directly to human outcomes. Studies in longevity and aging applications represent evolving research and should not be interpreted as evidence of established efficacy for elective human applications. All clinical decisions should involve physician evaluation.
2005
Conboy et al. — Heterochronic Parabiosis
Nature, 2005 · PMID 15716955
This foundational study demonstrated that exposing aged tissue stem cells to a younger circulatory environment produced measurable reversal of multiple cellular aging markers in mice connected to younger partners. Critically, the researchers found that less than 0.1% of regenerated tissue came from the younger animal — meaning the effects were driven by circulating plasma factors, not cell migration.
Key insight: Circulating plasma factors — not cell replacement — appear to modulate tissue aging. Young animals joined to old partners showed impaired regeneration, pointing to actively harmful factors in aged blood as a primary driver. This supported a broader hypothesis, later tested with plasma exchange, that aging biology is shaped by what accumulates in blood over time.
View on PubMed ↗2011
Villeda et al. — The Aging Systemic Milieu and Neurogenesis
Nature, 2011 · PMID 21886162
Villeda and colleagues showed that the aged plasma environment actively inhibits neurogenesis and cognitive function. Young mice exposed to old blood showed reduced neurogenesis; old mice exposed to young blood showed improvement. The chemokine CCL11 (eotaxin) was identified as a pro-aging signaling factor elevated in aged plasma that inhibits brain cell regeneration.
Key finding: Specific molecules in old blood were identified as directly harmful to brain function — not just absent youthful factors.
View on PubMed ↗2016
Rebo et al. — Old Blood Inhibits Multiple Tissues
Nature Communications, 2016 · PMID 27874859
Rebo et al. isolated the effects of blood exchange from confounding parabiosis variables. A single exchange of old blood into young mice decreased muscle regeneration, liver regeneration, and neurogenesis. Old blood's inhibitory effects were more pronounced than young blood's beneficial effects — particularly for neurogenesis.
Key pivot: Dilution of pro-aging factors may be more therapeutically important than addition of youthful ones.
View on PubMed ↗2020
Mehdipour et al. — Neutral Blood Exchange (Animal-to-Human Bridge Study)
Aging, 2020 · PMID 32474458
This study showed that young blood is not necessary to produce biological changes. Replacing 50% of old plasma with saline plus 5% albumin — effectively the animal-model equivalent of therapeutic plasma exchange — reversed multiple measured markers of tissue aging in old mice across muscle, liver, and hippocampus, with effects matching or exceeding heterochronic parabiosis. Critically, this study also analyzed human plasma samples from TPE procedures: proteomic analysis revealed that age-associated inflammatory proteins decreased while certain proteins linked to cellular repair increased after treatment.
Bridge finding: Dilution alone — not young blood — produced measurable changes in biological aging markers. Human TPE plasma samples showed the same molecular pattern, suggesting translational relevance.
View on PubMed ↗2020
Boada et al. — AMBAR Trial (Alzheimer's Disease)
Annals of Neurology, 2020 · DOI 10.1002/ana.25582
The AMBAR trial evaluated plasma exchange with albumin replacement in patients with mild-to-moderate Alzheimer's disease over approximately 14 months. The protocol included an initial series of weekly treatments followed by monthly maintenance. Published results showed that treated patients in certain subgroups experienced statistically significant reductions in functional and cognitive decline compared to controls. The clinical implications of these findings remain under active investigation.
Clinical note: Published research has investigated whether TPE with albumin may slow progression in certain Alzheimer's patients. Results remain under active investigation and should not be interpreted as an established treatment for Alzheimer's disease.
View Publication ↗2022
Kim, Kiprov et al. — First Human Biological Age Study
GeroScience, 2022 · PMID 35999337
The first clinical study to demonstrate that TPE measurably reduces human biological age. Older adults receiving five or more TPE sessions showed reductions in biological age of approximately 1–2 years as measured by epigenetic clocks and proteomic markers. The study found restored immune profiles, reduced cellular senescence markers, reduced DNA damage indicators, and normalization of key signaling pathways (JAK-STAT, MAPK, TGF-beta, NF-κB).
First-in-human finding: Published research has shown that repeated TPE is associated with measurable reductions in epigenetic and proteomic markers of biological age. Long-term clinical outcomes remain under investigation.
View on PubMed ↗2022
Kiprov et al. — Long COVID Case Report
F1000Research, 2022 · DOI 10.12688/f1000research.74534.2
A documented case of long COVID treated with plasma exchange was associated with rapid improvement in respiratory symptoms, resolution of cognitive impairment, restoration of physical endurance, and normalization of inflammatory laboratory markers. This represents early-stage, single-case evidence in a condition characterized by persistent immune dysregulation and circulating inflammatory factors.
Evidence level: Single case report. Early-stage only. Further clinical investigation is needed before any conclusions about efficacy can be drawn.
View Publication ↗2025
Fuentealba, Kiprov et al. — Circulate Trial (Multi-Omics)
Aging Cell, 2025 · PMID 40424097
This randomized clinical trial compared different TPE regimens across 30 participants using 36 DNA methylation clocks alongside proteomics, metabolomics, lipidomics, cytomics, and glycomics — one of the most comprehensive biological aging assessments applied to a TPE trial to date. Four arms were tested: biweekly TPE + IVIG, biweekly TPE without IVIG, monthly TPE, and a sham control. The TPE + IVIG arm produced the strongest measurable reduction — approximately 2.61 years in epigenetic age measures after three sessions. Effects observed in TPE-only arms were present but less consistent. Effects across all arms were transient with the modest schedule used, leading researchers to conclude that more intensive or prolonged protocols would likely produce more durable results.
Important distinction: The 2.61-year reduction in measured biological age was observed specifically in the TPE + IVIG arm — not in TPE alone. Results are promising across the research field; optimal protocols and long-term clinical outcomes remain under active investigation.
View on PubMed ↗2026
Weinstein et al. — TPE and Circulating Microplastics
Journal of Clinical Apheresis, 2026 · DOI 10.1002/jca.70135
The first peer-reviewed clinical study to measure whether therapeutic plasma exchange can reduce circulating microplastics in human patients. 114 patients across 174 single-plasma-volume TPE procedures. Circulating microplastic (MP) levels were measured before and after each session using a commercial dried-blood-spot assay (PlasticTox, Arrow Lab Solutions). The study found a clear threshold effect: patients starting with ≥30 MP/100µL saw a statistically significant, large-magnitude reduction (Cohen's d = 1.26, p<0.001). In patients below that threshold, results were limited or reversed by MP leaching from the plastic apheresis tubing set itself — an important structural confound the authors characterize in detail. The study does not establish whether reductions in circulating MP translate to a meaningful reduction in total body burden. Most patients in the study were seeking longevity support; others had POTS, ME/CFS, or long COVID.
View Publication ↗ASFA Evidence Tier by Application Area
Neurological / Autoimmune
Category I–II
Renal / Metabolic
Category II–III
Cardiovascular (Lp(a)/LDL)
Established
Inflammatory / Post-Viral
Investigational
Aging / Longevity
Emerging
Based on ASFA category framework (Journal of Clinical Apheresis). Category I = first-line therapy; Category II = second-line. Investigational/Emerging = not yet ASFA-classified. Editorial synthesis — refer to current ASFA guidelines for complete classification.
View ASFA Guidelines ↗TPE is used across a spectrum of clinical contexts — from established, guideline-supported medical indications to investigational applications currently being studied in clinical trials.
Important Scope Limitations
What TPE Is Not
Not a proven longevity treatment or established anti-aging therapy
Not a treatment for or cure of Alzheimer's disease
Not a replacement for standard medical care or established treatments
Not an established therapy for most wellness applications
Not appropriate for all patients — candidacy requires physician evaluation
Not a detoxification procedure in the functional medicine marketing sense
Established
Autoimmune & Neurological Conditions
TPE is a first-line or second-line treatment for conditions including Guillain-Barré syndrome, myasthenia gravis, thrombotic thrombocytopenic purpura (TTP), CIDP, and ANCA-associated vasculitis. In acute crises where pathogenic autoantibodies are driving rapid deterioration, the physical removal of those antibodies via TPE can produce effects within hours — faster than pharmacologic approaches that slow production rather than remove what is already circulating.
ASFA Category I–II
Established
Cardiovascular — Lipoprotein Apheresis
A specialized form of apheresis used for decades to treat patients with elevated lipoprotein(a) and LDL cholesterol who are at high cardiovascular risk and have not responded adequately to medication. Each session can reduce Lp(a) and LDL levels by approximately 60–75%,
Waldmann 2016 with ongoing therapy required to maintain results. Observational data suggest a reduction in cardiovascular risk in certain high-risk populations.
Long-standing clinical use
Evolving Research
Biological Aging & Longevity
Published clinical research has shown that repeated TPE is associated with measurable reductions in epigenetic and proteomic markers of biological age. The 2022 GeroScience study found reductions of approximately 1–2 years in measured biological age after five or more sessions.
Kim 2022 The 2025 Aging Cell trial found a reduction of approximately 2.61 years in the TPE + IVIG arm after three sessions.
Fuentealba 2025 Long-term clinical outcomes — effects on disease development, lifespan, or symptom burden — are not yet established.
Investigational — evolving evidence
Evolving Research
Cognitive Health & Alzheimer's Risk
The AMBAR trial explored plasma exchange with albumin replacement in mild-to-moderate Alzheimer's patients over 14 months.
Boada 2020 Published results showed statistically significant differences in functional and cognitive decline in certain subgroups. Separately, protocols are being evaluated for patients with genetic risk factors (APOE4 carriers) or a family history, as a potential risk-mitigation approach. TPE should not be characterized as a treatment for Alzheimer's disease.
Evolving — cautious framing required
Investigational
Post-Viral Syndromes & Immune Dysregulation
A documented case report (Kiprov et al., 2022) described rapid clinical improvement in a long COVID patient following plasma exchange, including resolution of respiratory symptoms, cognitive improvement, and normalization of inflammatory markers. Both long COVID and conditions like POTS and ME/CFS are thought to involve persistent autoantibodies and immune dysregulation, making them logical investigational candidates for TPE. Evidence remains early-stage.
Early-stage — case report level
Emerging
Protein-Bound Heavy Metals & Contaminants
TPE has documented application in removing protein-bound heavy metals including mercury, which are not easily cleared by the kidneys or removed by standard dialysis. Specialized protocols involving intensive initial sessions with laboratory monitoring are used in this context. Investigational research is also exploring whether plasma exchange may influence the circulation of certain environmental contaminants more broadly; this work remains preliminary and unpublished for most applications.
Heavy metals: case-documented · Environmental: investigational
Microplastics — First human evidence (2026)
Microplastics
A study published in the Journal of Clinical Apheresis in May 2026 is the first peer-reviewed research to measure whether therapeutic plasma exchange can reduce circulating microplastics in human patients.Weinstein 2026 · DOI: 10.1002/jca.70135 114 patients across 174 single-plasma-volume procedures. The core result is genuinely promising — but it comes with a structural limitation that determines whether any given patient would benefit.
At baseline levels ≥30 MP/100µL, TPE produced a statistically significant, large-effect reduction (Cohen's d = 1.26, p<0.001). At lower baseline levels, results were limited or reversed by MP leaching from the plastic apheresis tubing itself. The study does not establish whether circulating reductions translate to a meaningful reduction in total body burden.
For a detailed breakdown of findings and clinical implications, see: Can Therapeutic Plasma Exchange Reduce Microplastics? What the First Human Study Actually Found →
Early evidence — circulating MP reductionNo published peer-reviewed evidence
Mold & Mycotoxin Illness
The use of TPE for mold illness, mycotoxin exposure, or "toxic mold syndrome" has no published peer-reviewed evidence supporting its efficacy. Mycotoxins vary significantly in their protein-binding characteristics and plasma residence — many are primarily metabolized through the liver and excreted through the gut rather than circulating in plasma in forms efficiently captured by apheresis. This application is speculative and not recognized by any major medical guideline body.
Patients should ask any provider making mold-related TPE claims to cite peer-reviewed published research — and to clarify whether their evidence is based on completed studies or work still in progress.
No evidenceA consistent pattern emerges across the clinical literature: TPE is not used as a single-session intervention. Protocols involve an initial treatment series, early measurable response, and often a maintenance phase. The following compares published study designs.
| Study | Condition | Initial Series | Maintenance | Duration | Notes |
|---|
| Boada et al., 2020AMBAR Trial | Alzheimer's disease | Weekly × 6 | Monthly × 12 months | ~14 months | Loading + maintenance structure; statistically significant differences in decline observed in certain subgroups |
| Kim et al., 2022GeroScience | Biological aging | 5+ sessions, approximately monthly | Continued monthly | Several months | Cumulative effects; biological age reductions of 1–2 years by epigenetic and proteomic measures |
| Fuentealba et al., 2025Aging Cell — Circulate Trial | Aging / immune health | Biweekly in first week, 3-week break, cycle repeated; or monthly × 6 | Monthly × 6 (alternative arm) | ~3–6 months | Biweekly + IVIG arm showed strongest effect; ~2.61-year reduction in measured biological age after 3 sessions |
| NCT05054894Frailty Study, ClinicalTrials.gov | Age-related frailty | 6 total treatments | Weekly or monthly depending on severity | Variable | Defined initial series required before evaluating clinical response |
| Kiprov et al., 2022F1000Research | Long COVID | 2 treatments within ~5 days | 1 additional treatment ~2 months later | ~2 months | Rapid clinical improvement after initial sessions; single case report only |
| Waldmann & Parhofer, 2016Journal of Lipid Research | Lp(a) / LDL (cardiac risk) | Ongoing — not a defined loading phase | Weekly or biweekly indefinitely | Indefinite | Ongoing therapy required to maintain 60–75% lipid reduction per session |
Across these studies, early sessions tend to produce the most measurable biological changes, while later sessions and maintenance phases appear to sustain effects. This pattern — early response, diminishing marginal return, maintenance requirement — is consistent with other blood-based interventions and informs how individualized protocols are structured in clinical practice.
While protocols vary by clinic, indication, and patient profile, the following describes a structured outpatient TPE process at a physician-supervised apheresis facility.
Step 01
Physician Screening & Candidacy Review
Medical history, laboratory evaluation, and clinical assessment to determine whether TPE is appropriate and which protocol fits the patient's profile.
Step 02
Individualized Treatment Planning
Physician calculates total plasma volume from body weight and hematocrit. Exchange volume is set to achieve a clinically relevant percentage — not a fixed amount applied uniformly.
Step 03
IV Access & Apheresis Setup
Peripheral IV access established. Apheresis machine primed. RN supervises all setup. Medications withheld per protocol (ACE inhibitors discontinued 48hrs prior).
Step 04
Exchange Procedure
Blood processed continuously through apheresis circuit. Plasma separated and replaced with albumin solution. Typical duration: 3–5 hours per session depending on exchange volume.
Step 05
Post-Procedure Monitoring & Follow-Up
Patient monitored post-procedure. Labs reviewed. Protocol adjusted for subsequent sessions based on response and clinical judgment.
A typical single-volume exchange — 1× total plasma volume — clears approximately 63% of circulating plasma substances.ASFA A 1.5-volume exchange reaches approximately 75–80% clearance. Exchange volume is determined by patient size and clinical goals, not by a fixed standard protocol.
For readers interested in procedural specifics beyond the research framework presented here, a detailed overview of how plasma exchange is performed at our Scottsdale clinic outlines evaluation, protocol design, and treatment-day workflow.
TPE is not appropriate for all patients. A structured candidacy evaluation — including medical history review and laboratory assessment — is required before treatment can be recommended. Patients evaluating suitability can see who may be a candidate for PlasmaRestore™ and review the clinical factors considered before treatment is recommended.
Typical Inclusion Criteria
- Generally good health with stable vital signs
- Chronic conditions present but clinically stable
- Hemoglobin ≥ 12 g/dL (men) or ≥ 11 g/dL (women)
- Platelet count ≥ 100,000/µL
- Fibrinogen ≥ 100 mg/dL
- Normal kidney and liver function on labs
- Able to remain seated or reclined with arms still for procedure duration
- Written informed consent provided
Contraindications / Disqualifying Factors
- Known allergy to albumin, gamma globulin, or blood products
- Active ACE inhibitor use (must be discontinued 48 hrs prior)
- Clinically unstable chronic conditions
- Laboratory values outside acceptable thresholds
- Inability to maintain IV access or tolerate procedure duration
- Refusal or inability to provide informed consent
Note on Lab ThresholdsThe criteria above reflect commonly published outpatient TPE candidacy parameters from clinical practice literature. Physician discretion applies in evaluating individual cases. These thresholds are not universal across all providers or indications. Any candidacy determination requires direct physician evaluation.
Pre-Procedure Considerations
Patients preparing for a TPE session should hydrate well the day prior, eat a light meal beforehand, and avoid high-fat or high-citrate foods and liquids in the hours before treatment. Citrate is used as an anticoagulant in the apheresis circuit, and excess dietary citrate can interact with the process. Medications are typically withheld on treatment days until after the procedure is complete.
TPE costs vary significantly depending on setting, indication, geographic market, and insurance coverage. The following reflects available information across hospital, outpatient, and elective contexts.
Hospital / Inpatient Setting
$8,000–$15,000+
Per session in acute hospital settings. Billed through insurance for covered indications. High variance based on facility, market, and clinical complexity.
Outpatient / Elective Setting
$6,000–$12,000
Per session range in outpatient and elective investigational contexts. Cash-pay. The lower end of this range typically reflects multi-session package pricing (4+ sessions prepaid) rather than single-session rates. Reflects clinical staff, apheresis equipment, disposable circuit, albumin, and physician oversight.
Insurance Coverage
Indication-Dependent
Coverage exists for established medical indications (neurological, autoimmune, hematologic). Elective or investigational applications are generally not covered and are provided on a cash-pay basis. Verify with your insurer based on your specific indication.
Primary Cost Drivers
What Affects Price
Albumin volume used (scales with patient size and target exchange percentage), session length, apheresis equipment and disposable circuit, RN and physician time, monitoring, and geographic market. Volume-adjusted protocols typically require more albumin than fixed-volume alternatives.
Note on Protocol Volume & CostTreatment volume should be calculated from a patient's individual total plasma volume — derived from body weight and hematocrit — to achieve a clinically consistent exchange percentage. A fixed, standardized volume (e.g., 2 liters albumin regardless of patient size) may under-treat larger patients relative to their actual plasma volume. Volume-adjusted protocols deliver a more consistent exchange percentage across patients of different sizes and profiles.
Not all TPE protocols are clinically equivalent. Key variables differ meaningfully across providers and should be part of any informed patient evaluation when comparing options.
| Variable | Standardized Protocol | Individualized Protocol |
|---|
| Exchange Volume | Fixed amount applied uniformly regardless of patient size | Calculated from individual total plasma volume using body weight and hematocrit |
| % Plasma Exchanged | Varies with patient size — larger patients may receive a lower effective percentage | Targeted to achieve a consistent, clinically relevant exchange percentage per patient |
| Physician Involvement | Ranges from minimal to moderate depending on provider structure | Active oversight: candidacy evaluation, treatment planning, protocol adjustment, follow-up review |
| Session Frequency | Often fixed regardless of patient response or biomarkers | Adjusted based on biomarkers, clinical response, and physician judgment |
| Follow-Up Structure | Variable — not consistently built into standard packages | Structured monitoring and clinical assessment between sessions and post-series |
Patients evaluating TPE providers should ask specifically how treatment volume is calculated, what physician oversight looks like throughout the process, and how the protocol is adjusted based on response. These distinctions have meaningful implications for the clinical consistency of each procedure and the overall quality of the treatment series.
The quality of a TPE program is determined by factors that are not always visible on a clinic website. This checklist is designed to help you evaluate providers before committing to a treatment series.
Physician & Clinical Credentials
- → Is the supervising physician board-certified in nephrology, hematology, or a field with direct apheresis training?
- → Does the physician have direct hands-on experience performing or supervising therapeutic plasma exchange — not just prescribing it?
- → How many RNs are assigned to each patient during a session — and are they specifically trained in apheresis nursing?
- → Does the nursing team have experience from hospital-based apheresis settings, not only outpatient wellness clinics?
Protocol & Volume Calculation
- → Is my treatment volume calculated individually based on my body weight and hematocrit — or is a fixed volume applied to all patients?
- → What percentage of my total plasma volume will be exchanged per session?
- → What replacement fluid is used — 5% albumin, fresh frozen plasma, or other — and why?
- → How is the protocol adjusted if my response differs from expectations across the series?
Candidacy & Evaluation Process
- → Is there a structured candidacy evaluation — including labs, medical history review, and clinical assessment — before any treatment is recommended?
- → What lab values are required before treatment can proceed?
- → Are there conditions or medications that would make me ineligible — and how is that determined?
Monitoring & Follow-Up
- → What monitoring occurs during the procedure — vital signs, circuit pressure, patient status?
- → What labs are reviewed between sessions, and are results discussed with the physician?
- → Is there a post-series evaluation — and how is the decision made about maintenance sessions?
- → What is the plan if I experience side effects during or after a session?
Why These Questions MatterTherapeutic plasma exchange is increasingly offered at outpatient clinics with varying levels of clinical rigor. The questions above are designed to distinguish between providers with deep apheresis expertise and those adapting from adjacent wellness or aesthetics backgrounds. The procedure itself is the same across settings — what differs is the depth of evaluation, the precision of protocol design, and the clinical oversight surrounding it.
Is therapeutic plasma exchange the same as donating plasma?
No. Plasma donation is a voluntary process in which a healthy individual contributes plasma for pharmaceutical manufacturing or transfusion. The donor's blood cells are returned, but the plasma is kept by the collection center and the donor is compensated. Therapeutic plasma exchange is a physician-prescribed clinical procedure in which the patient's own plasma is removed and replaced with a substitute fluid — typically albumin — for a medical or investigational purpose. The patient receives treatment, not compensation. The settings, oversight, and intent are entirely different.
What is the difference between plasmapheresis and therapeutic plasma exchange?
Plasmapheresis is a broad term for any process that separates plasma from blood cells. Therapeutic plasma exchange (TPE) is a specific type of plasmapheresis in which a large volume of plasma is removed and replaced with a substitute fluid. The terms are sometimes used interchangeably in lay publications, but in clinical practice TPE specifically refers to the therapeutic procedure with volume replacement — which is the more intensive and clinically meaningful application.
How much of my plasma is removed in a single session?
A single-volume exchange — where the volume treated equals your estimated total plasma volume (typically 3–4.5 liters in a standard adult) — removes approximately 63% of plasma-resident substances.
ASFA At 1.5 plasma volumes, that increases to roughly 75–80%. The volume should be calculated for you individually based on your body weight and hematocrit. A fixed 2-liter protocol, applied regardless of size, will under-exchange a larger patient — sometimes significantly.
How long does a TPE session take?
A typical outpatient session takes approximately 3–5 hours, depending on the exchange volume being treated. Because treatment volume scales with patient size and target exchange percentage, larger patients may require longer sessions. Patients are typically seated or reclined throughout, with IV access in one or both arms.
Why are multiple treatments typically recommended?
The clinical literature consistently shows that the biological effects of plasma exchange are cumulative. Initial sessions tend to produce the most measurable changes in biomarkers. Subsequent sessions help sustain those effects, as the body continues producing the proteins and antibodies being removed. Published study protocols — including the AMBAR trial, the GeroScience longevity study, and the Circulate Trial — all use multi-session designs, with initial treatment series followed by maintenance phases in most cases.
What does the research show about TPE for biological aging?
Published clinical research has shown that repeated TPE is associated with measurable reductions in epigenetic and proteomic markers of biological age. The 2022 GeroScience study (Kim, Kiprov et al.) found reductions of approximately 1–2 years in measured biological age after five or more sessions. The 2025 Aging Cell trial (Fuentealba, Kiprov et al.) found a reduction of approximately 2.61 years in epigenetic age measures — specifically in the arm combining TPE with IVIG, not TPE alone. These are changes in laboratory-assessed biological markers; long-term clinical outcomes — effects on disease development, lifespan, or symptom burden — remain under active investigation and are not yet established.
Is TPE covered by insurance?
Insurance coverage for TPE exists for established medical indications — including certain neurological, autoimmune, and hematologic conditions where TPE is recognized as a standard or first-line treatment. Elective or investigational applications, including longevity-focused protocols, are generally not covered by insurance and are provided on a cash-pay basis. Patients should verify coverage with their insurer based on their specific clinical situation and indication.
What are the risks of TPE?
TPE is a medical procedure that carries real risks requiring a properly equipped and experienced clinical setting. The most common side effects include low blood pressure, fatigue, and electrolyte shifts. Because plasma carries clotting factors, those are removed along with the targeted substances — creating a temporary and manageable reduction in clotting capacity. Less commonly, patients may experience allergic reactions to the replacement fluid or issues related to IV access. The risks of TPE are manageable in a supervised clinical setting but are meaningful enough to require proper screening, physician oversight, and post-procedure monitoring.
What should I ask when evaluating a TPE provider?
Key questions include: How is my treatment volume calculated — is it individualized to my body weight and plasma volume, or is a fixed amount applied regardless of size? What is the physician's background specifically in therapeutic apheresis? Is the supervising physician a specialist or board-certified in a relevant field such as nephrology? Is there a structured candidacy evaluation before any treatment is recommended? What monitoring occurs during and after sessions? How many nurses are assigned to the procedure — and are they trained specifically in apheresis? How is the protocol adjusted based on my response? The answers to these questions help distinguish between providers offering standardized packages and those delivering clinically individualized care.
Why does it matter whether the supervising physician is a specialist in apheresis or nephrology?
Therapeutic plasma exchange is an apheresis procedure that operates at the intersection of nephrology, hematology, and clinical medicine. Physicians with board certification in nephrology or direct subspecialty training in apheresis have hands-on experience with the physiologic effects of large-volume plasma exchange — including fluid shifts, electrolyte management, clotting factor replacement, and adverse event recognition. A provider whose medical background is primarily in aesthetics, general wellness, or functional medicine may not have the same depth of procedural experience. For a procedure that replaces 1–1.5 times your total plasma volume, the oversight physician's clinical background is a meaningful differentiator.
Does the number of nurses present during a TPE session matter?
Yes — and for a practical reason that matters. TPE requires someone in the room continuously throughout the procedure. That means a single nurse model creates a real gap: nurses need to leave the room to retrieve supplies, step out briefly, or handle competing demands. A well-run outpatient apheresis clinic operates with two nurses per session to ensure uninterrupted monitoring. One manages the apheresis machine and circuit; the other supports the patient, handles any supply needs, and provides coverage if the first must briefly step away. Unlike an IV infusion where a patient can be checked in on periodically, TPE requires active, continuous supervision — vital sign monitoring, circuit management, and the ability to respond immediately to any hemodynamic changes. When evaluating a clinic, ask directly: how many nurses are assigned to a session, and is there continuous coverage throughout?
Is TPE an effective treatment for microplastics or mold toxicity?
These are two distinct questions that deserve separate answers. For microplastics: a 2026 peer-reviewed study published in the Journal of Clinical Apheresis (Weinstein et al., DOI: 10.1002/jca.70135) is the first clinical evidence that TPE can measurably reduce circulating microplastics — but only in patients with higher baseline levels (≥30 MP/100µL), and only for circulating burden, not total body burden. At lower starting levels, MP leaching from the plastic apheresis tubing itself limited or reversed the effect. Real findings, meaningful limitations — and not yet a basis for broad clinical claims. For mold and mycotoxins: there is no published peer-reviewed evidence. Mycotoxins are largely metabolized through the liver and excreted through the gut rather than circulating in plasma in a form efficiently captured by apheresis. Any provider making mold-related TPE claims should be asked to cite the peer-reviewed studies they are relying on.